Open an account

Cyclerion Therapeutics

KRSA · NASDAQ

$31.03−$0.38 (−1.21%)TodayMarket closed ·
Prev close $31.41

About KRSA

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1 full-time employees. The company went IPO on 2019-03-18. The firm is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. The company is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The firm has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

Employees
1
Headquarters
Cambridge, Massachusetts
Listed
Mar 18, 2019
Sector
Health Care
Industry
Biotechnology
Website
cyclerion.com

KRSA key statistics

Market cap
1.41B
Price-earnings ratio
—
Dividend yield
—
Average volume
137.82K
Volume
105.83K
Open price
$31.24
High today
$32.06
Low today
$29.97
52 Week high
$37.27
52 Week low
$21.00

Cyclerion Therapeutics (KRSA) at a glance

Cyclerion Therapeutics (KRSA) last traded at $31.03, with a market cap of 1.41B.

Today the stock has traded between $29.97 and $32.06. The current price is 3.6% above the day's low and 3.2% below its high.

Volume so far is 105.83K shares, below the average of 137.82K shares a day.

Over the past year Cyclerion Therapeutics has ranged from $21.00 to $37.27, and now sits 62% of the way up that range.

Cyclerion Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q4 FY25 it reported -$0.21 per share against an estimate of -$0.3876.

The average analyst price target is $0.00, 100.0% below the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 2 analystsAvg $0.00
Low
$0.00
Now
$31.03
High
$0.00

KRSA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 29.4% on average.

  1. Q4 FY21: reported -$6.60 per share against an estimate of -$6.12
  2. Q1 FY22: reported -$6.00 per share against an estimate of -$7.34
  3. Q2 FY22: reported -$6.20 per share against an estimate of -$6.12
  4. Q3 FY22: reported -$4.80 per share against an estimate of -$6.32
  5. Q3 FY23: reported -$0.93 per share against an estimate of -$0.3366
  6. Q2 FY25: reported -$0.11 per share against an estimate of $0.00
  7. Q3 FY25: reported -$0.30 per share against an estimate of $0.00
  8. Q4 FY25: reported -$0.21 per share against an estimate of -$0.3876

Similar companies

Companies in the same industry as Cyclerion Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.